Catheter Cardiovasc Interv 2021 Jun;97(7):1479-1480
Department of Cardiology, Texas Heart Institute, Hoston, Texas, USA.
Eur Heart J Case Rep 2020 Dec 23;4(6):1-6. Epub 2020 Oct 23.
Division of Interventional Cardiology, Onassis Cardiac Surgery Center, 356 Syngrou av, 176 74 Athens, Greece.
Background: Valve-in-valve transcatheter aortic valve implantation (TAVI) has emerged as a competent alternative for the treatment of degenerated bioprosthetic valves after surgical aortic valve replacement, or during TAVI procedure as a bailout option. Herein, we report a rare case of a self-expandable Medtronic Evolut R valve into a failing Medtronic CoreValve, with the use of modern pre-TAVI imaging screening, suggesting the proper procedural design steps for so complicated implantations.Case Summary: A frail 78-year-old woman with a degenerated Medtronic Core Valve 26 mm bioprosthesis, implanted in 2011 due to severe aortic stenosis, was referred to our hospital due to worsening dyspnoea New York Heart Association III. Read More
Rev Med Chil 2021 Jan;149(1):137-141
Instituto Cardiovascular, Hospital Clínico San Carlos, Madrid, España.
Reintervention of a mitral degenerated bioprosthesis has a high surgical risk, especially in elderly patients with multiple comorbidities. We report a 74 years old female with two previous cardiac surgical procedures and a new structural mitral bioprosthesis deterioration with severe mitral regurgitation. Considering her high-surgical risk, a fully percutaneous treatment was performed with a balloon-expandable aortic valve in mitral position (valve-in-valve) through a transseptal approach with a favorable outcome. Read More
Semin Thorac Cardiovasc Surg 2021 Jun 4. Epub 2021 Jun 4.
Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Michigan. Electronic address:
The long-term survival and reoperation rate in chronic renal failure (CRF) on hemodialysis (HD) patients after aortic valve/root replacement (AVR/ARR) with a stentless bioprosthesis is unknown. From 1992-2015, 1941 patients underwent AVR/ARR with stentless valve for primary indications of aortic stenosis/insufficiency, root aneurysm, and acute type A aortic dissection, including 93 CRF-HD (64 new-onset postoperative HD, and 29 preoperative HD) and 1848 non-CRF-HD. Data was obtained from the STS database, retrospective chart review, administered surveys and national death index data. Read More
Circ Cardiovasc Interv 2021 Jun 7:CIRCINTERVENTIONS120010440. Epub 2021 Jun 7.
IRCCS Policlinico S. Donato, Milan, Italy (L.T., M.A., N.B., A.P.R., M.C., F.D.M., G.B., F.B.).
Background: Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in the treatment of patients with severe aortic stenosis. However, the durability of bioprostheses is still a matter of concern, and little is known about the management of degenerated TAV. We sought to evaluate the outcomes of patients with a degenerated TAV treated by means of a second TAVR. Read More